medigraphic.com
ISSN 1995-9427 (Print)

2021, Number 3

<< Back Next >>

Invest Medicoquir 2021; 13 (3)

Treatment of cranio-cervical dystonia with botulinum toxin type A (Xeomen)

Maragoto RC, Vera CH, Gómez FL, Ricardo FY, Rodríguez LA, Maragoto PE, Zaldivar BM, Marín HT

Language: Spanish
References: 21
Page: 1-9
PDF size: 52.59 Kb.


ABSTRACT

Introduction. Cranio-cervical dystonia constitutes one of the most frequent segmental dystonia. Numerous treatments have been tried for this disease, botulinum toxin type A has been used as a treatment since the 80's. Methods. Prospective study in 23 patients with cranio-cervical dystonia to whom botulinum toxin type A (Xeomen) was applied. Results. The onset of the clinical effect was 5.65 days. The maximum effect at 28.35 days. The maximum duration of effect of 3.67 months. After the administration of the toxin, there is a 60.20% increase in activity, 2 patients had complications (palpebral ptosis and lacrimation), this results in a tolerance level to botulinum toxin type A of 87%. Conclusions. Botulinum toxin was effective in the treatment of cranio-cervical dystonia, tonic blepharospasm responded better and the response was evident from the day of application. The complications of the procedure were minimal.


REFERENCES

  1. Fahn S. The varied clinical expressions of dystonia. In Jankovic J, ed Movement disorders. Neurologic clinics. Vol 2. Philadelpfia: WB Saunders, 1984; pp 541-554.

  2. Meige H. Les convulsions de la face: une forme clinique de convulsione faciales, bilateral y mediane. Rev Neurol (Paris) 1910; 21: 437-443.

  3. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088-1091.

  4. Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W; Austrian Botulinum Toxin and Dystonia Study Group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002 Jul;249(7):842-6.

  5. Fahn S, Marsden CD, Calne DB. Dystonia: advances in neurology. Vol 50. New York: Raven Press, 1988.

  6. Frueh BR, Felt DP, Wojno TH, Muesh DC. Treatment of blepharospasm with botulinum toxin: A preliminary report. Arch Ophfhalmol 1984; 102: 1464-1468.

  7. Mitchell F. Brin. Botulinum Toxin: Chemistry, Pharmacology, Toxicity and Inmunology. Muscle Nerve (suppl. 6) 1997; S146-167.

  8. Singer C. Indications and management of botulinum toxin. Rev Neurol 1999 Jul 16-31;29(2):157-62.

  9. Huber A. Botulinum toxin and the eye. Curr Probl Dermatol 2002;30:227-35 10.O'Day J. Use of botulinum toxin in neuro-ophthalmology. Curr Opin Ophthalmol 2001 Dec;12(6):419-22.

  10. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg 1998 Sep;14(5):305-17.

  11. Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998;78:231-5.

  12. Tolosa E, martí MJ. Blepharospasm-oromandibular dystonia symdrome (Meige´s syndrome): clinical aspects Adv Neurol 1988; 49: 73-84.

  13. Thussu A, Barman CR, Prabhakar S. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation. Neurol India 1999 Sep;47(3):206-9.

  14. Grandas f, Elston J, Quinn N, Marden CD. Blepharospasm: review of 264 patients. J Neurol Neurosurg Psychiatry 1988; 51: 767-772.

  15. Mauriello JA Jr, Dhillon S, Leone T, Pakeman B, Mostafavi R, Yepez MC. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 1996 Dec;80(12):1073-6.

  16. Andrade LA, Borges V, Ferraz HB, Azevedo-Silva SM. Botulinum toxin A: experience in the treatment of 115 patients. Arq Neuropsiquiatr 1997 Sep;55(3B):553-7.

  17. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997 Apr;235(4):197-9.

  18. Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol 2001 Dec;36(7):398-403.

  19. Boghen DR, Lesser RL Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2000 Sep;2(5):393-400.

  20. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002 Nov;17(6):1288-93.

  21. Dutton JJ. Botulinum-A toxin in the treatment of cranio-cervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996 Jul-Aug;41(1):51-65.




2020     |     www.medigraphic.com